LT1747001T - Prasiveržiančio kraujavimo reguliavimas, vartojant hormoninius kontraceptikus prolonguotais režimais - Google Patents

Prasiveržiančio kraujavimo reguliavimas, vartojant hormoninius kontraceptikus prolonguotais režimais

Info

Publication number
LT1747001T
LT1747001T LTEP05740127.5T LT05740127T LT1747001T LT 1747001 T LT1747001 T LT 1747001T LT 05740127 T LT05740127 T LT 05740127T LT 1747001 T LT1747001 T LT 1747001T
Authority
LT
Lithuania
Prior art keywords
management
breakthrough bleeding
hormonal contraceptive
contraceptive regimens
extended
Prior art date
Application number
LTEP05740127.5T
Other languages
English (en)
Inventor
Andreas Sachse
Patricia J. Sulak
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT1747001(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of LT1747001T publication Critical patent/LT1747001T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
LTEP05740127.5T 2004-04-30 2005-04-29 Prasiveržiančio kraujavimo reguliavimas, vartojant hormoninius kontraceptikus prolonguotais režimais LT1747001T (lt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10
PCT/EP2005/004777 WO2005105103A2 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Publications (1)

Publication Number Publication Date
LT1747001T true LT1747001T (lt) 2019-01-25

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP05740127.5T LT1747001T (lt) 2004-04-30 2005-04-29 Prasiveržiančio kraujavimo reguliavimas, vartojant hormoninius kontraceptikus prolonguotais režimais

Country Status (29)

Country Link
US (3) US8163721B2 (lt)
EP (1) EP1747001B1 (lt)
JP (4) JP2007535519A (lt)
KR (4) KR101812160B1 (lt)
CN (1) CN103127156A (lt)
AR (1) AR048722A1 (lt)
AU (1) AU2005237255B2 (lt)
BR (1) BRPI0510493A (lt)
CA (1) CA2562296A1 (lt)
CR (1) CR8709A (lt)
DK (1) DK1747001T3 (lt)
EA (2) EA031227B1 (lt)
EC (1) ECSP066999A (lt)
ES (1) ES2704999T3 (lt)
HU (1) HUE041475T2 (lt)
IL (1) IL178458A (lt)
LT (1) LT1747001T (lt)
MX (1) MXPA06012567A (lt)
MY (1) MY151322A (lt)
NO (1) NO341685B1 (lt)
NZ (1) NZ586107A (lt)
PA (1) PA8631801A1 (lt)
PE (1) PE20060467A1 (lt)
SG (2) SG10201701904TA (lt)
SI (1) SI1747001T1 (lt)
SV (1) SV2006002100A (lt)
TW (1) TWI374735B (lt)
UY (1) UY28875A1 (lt)
WO (1) WO2005105103A2 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
JP2012502988A (ja) * 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US9198919B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
PL3310345T3 (pl) 2015-06-18 2021-10-18 Estetra Sprl Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol
MX2017016276A (es) 2015-06-18 2018-06-19 Mithra Pharmaceuticals S A Unidad de dosificacion orodispersable que contiene un componente estetrol.
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
KR102217942B1 (ko) * 2015-06-23 2021-02-19 라보라토리오스 레온 파르마 에스에이 과한 체중으로 영향 받은 여성 환자를 위한 드로스피레논-기반의 피임제
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
ES2912929T3 (es) 2016-09-30 2022-05-30 Myovant Sciences Gmbh Métodos de tratamiento de fibromas uterinos y endometriosis
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CA2261689A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
PL199028B1 (pl) * 1999-08-31 2008-08-29 Bayer Schering Pharma Ag Kompozycja farmaceutyczna etynyloestradiolu i drospirenonu i jej zastosowanie
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
CR8709A (es) 2007-08-28
WO2005105103A2 (en) 2005-11-10
JP6134491B2 (ja) 2017-05-24
EA201200377A8 (ru) 2018-01-31
CN103127156A (zh) 2013-06-05
AU2005237255B2 (en) 2011-07-07
US20050250747A1 (en) 2005-11-10
IL178458A0 (en) 2008-04-13
SI1747001T1 (sl) 2019-02-28
KR101812160B1 (ko) 2017-12-27
SV2006002100A (es) 2006-02-15
DK1747001T3 (en) 2019-02-04
SG152288A1 (en) 2009-05-29
EP1747001B1 (en) 2018-10-10
SG10201701904TA (en) 2017-05-30
HUE041475T2 (hu) 2019-05-28
JP2013018787A (ja) 2013-01-31
EA031227B1 (ru) 2018-12-28
KR20150058555A (ko) 2015-05-28
TW200603781A (en) 2006-02-01
EA016625B1 (ru) 2012-06-29
KR20130022425A (ko) 2013-03-06
WO2005105103A3 (en) 2006-09-08
EA200601908A1 (ru) 2007-04-27
TWI374735B (en) 2012-10-21
PE20060467A1 (es) 2006-06-11
BRPI0510493A (pt) 2007-11-13
CA2562296A1 (en) 2005-11-10
MXPA06012567A (es) 2006-12-15
IL178458A (en) 2016-08-31
AR048722A1 (es) 2006-05-17
KR20070004919A (ko) 2007-01-09
JP2007535519A (ja) 2007-12-06
ECSP066999A (es) 2006-12-29
EP1747001A2 (en) 2007-01-31
US20150174142A1 (en) 2015-06-25
NZ586107A (en) 2012-05-25
JP6153967B2 (ja) 2017-06-28
EA201200377A1 (ru) 2012-08-30
US20120202779A1 (en) 2012-08-09
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
US8163721B2 (en) 2012-04-24
PA8631801A1 (es) 2006-11-09
NO341685B1 (no) 2017-12-18
MY151322A (en) 2014-05-15
UY28875A1 (es) 2005-11-30
JP2015187157A (ja) 2015-10-29
NO20065499L (no) 2006-11-29
JP2017048253A (ja) 2017-03-09
KR20160150113A (ko) 2016-12-28

Similar Documents

Publication Publication Date Title
SG10201701904TA (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
EP1841545A4 (en) ANTI-ADHESION AGENT OF ASPHALT
LT1811990T (lt) Priemonė prieš demodikozę
GB0403780D0 (en) Therapeutic agents
NO20071297L (no) Farmasøytisk sammenseting omfattende drospirenon og etynylestradiol
EP1844792A4 (en) THERAPEUTIC AGENT AGAINST OBSTIPATION
FI20041057A (fi) Pelkistysainekoostumus
GB0421298D0 (en) Cellular bandage
GB0400775D0 (en) Gel composition
GB0400193D0 (en) Therapeutic agents
GB0805741D0 (en) Prophylactic and therapeutic agents and uses therefor
GB0400310D0 (en) Anti-incrustation agent
GB0424497D0 (en) Anti-inflammatory agent
GB0408959D0 (en) Therapeutic agent
HU0500288D0 (en) Intra-uterine contraceptive
HU0500490D0 (en) Intra-uterine contraceptive
GB0402918D0 (en) Therapeutic agents
GB0400196D0 (en) Therapeutic agents
GB0403779D0 (en) Therapeutic agents
GB0418363D0 (en) Therapeutic methods and compositions for use therein
GB0407993D0 (en) Therapeutic methods and compositions for use therein
EP1759703A4 (en) IMMUNOSTIMULATING AGENT AND INTERF ROGEN
GB0422917D0 (en) Therapeutic compositions and devices
EP1712219A4 (en) AGENT DECREASING WRINKLES